Floatz logo

Etanidazole

Adult Myxopapillary Ependymoma

National Cancer Institute (NCI)Small moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Adult Myxopapillary Ependymoma cohort.

Asset / SponsorPhaseRating
FDOPA
Mayo Clinic
Early Phase 1CC
rg4733
National Cancer Institute (NCI)
Phase 1C
EF-5
National Cancer Institute (NCI)
Phase 1C

Same molecule, other indications

Etanidazole is also rated in:

adult anaplastic ependymomaDormant
D
Indicative ·
30 / 100
View asset →
anaplastic oligodendrogliomaDormant
D
Indicative ·
30 / 100
View asset →
anaplastic astrocytomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →